12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Acura, Pfizer sales and marketing update

Acura said that in 4Q13 Pfizer will expand commercialization of Oxecta oxycodone to health care providers who treat pain. Pfizer has exclusive rights to Acura's Aversion abuse-deterrent technology in North America for use in Oxecta. Acura receives tiered royalties of 5%-25%...

Read the full 194 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >